Subject    :    [2019 Feb;43(1)] Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Writer KDA
Date 2019-03-06 10:18:44 Hit 166
Diabetes Metab J. 2019 Feb;43(1):31-45. English.
Published online Dec 17, 2018.  https://doi.org/10.4093/dmj.2019.0011 
Copyright © 2019 Korean Diabetes Association
   
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong-ho Lee,1,2 Yongin Cho,1,2 Byung-Wan Lee,1,2 Cheol-Young Park,3 Dae Ho Lee,4 Bong-Soo Cha,1,2and Eun-Jung Rhee3
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
2Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
3Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
4Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea.

Corresponding author: Eun-Jung Rhee. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Email: ejrhee.lee@samsung.com 
 
Received January 14, 2019; Accepted February 01, 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

   
Keywords:
Diabetes mellitusDiagnosisEpidemiologyNon-alcoholic fatty liver disease
 

Articles - Reviews in DMJ
No. Subject Date Hit ↓
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 355
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 363
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 357
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 354
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 356
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 361
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 349
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 349
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 547
292 [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabe... 2019-04-18 1,405
291 [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-I... 2019-04-18 1,109
290 [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stro... 2019-04-18 1,181
289 [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced ... 2019-04-18 1,117
288 [2019 Apr;43(2)] Association between Changes in Anthropometric Indic... 2019-04-18 1,089
287 [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and F... 2019-04-18 1,120
286 [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consider... 2019-04-18 1,088
285 [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea E... 2019-04-18 1,096
284 [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part... 2019-04-18 1,083
283 [2019 Feb;43(1)] Higher High Density Lipoprotein 2 (HDL2) to Total H... 2019-03-06 202

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.